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Abstract 
Background: Wnt-5a is a member of the WNT family of secreted lipoglycoproteins, whose expression increases dur-
ing development; moreover, Wnt-5a plays a key role in synaptic structure and function in the adult nervous system. 
However, the mechanism underlying these effects is still elusive. MicroRNAs (miRNAs) are a family of small non-coding 
RNAs that control the gene expression of their targets through hybridization with complementary sequences in the 3′ 
UTR, thereby inhibiting the translation of the target proteins. Several evidences indicate that the miRNAs are actively 
involved in the regulation of neuronal function.
Results: In the present study, we examined whether Wnt-5a modulates the levels of miRNAs in hippocampal neu-
rons. Using PCR arrays, we identified a set of miRNAs that respond to Wnt-5a treatment. One of the most affected 
miRNAs was miR-101b, which targets cyclooxygenase-2 (COX2), an inducible enzyme that converts arachidonic acid 
to prostanoids, and has been involved in the injury/inflammatory response, and more recently in neuronal plasticity. 
Consistent with the Wnt-5a regulation of miR-101b, this Wnt ligand regulates COX2 expression in a time-dependent 
manner in cultured hippocampal neurons.
Conclusion: The biological processes induced by Wnt-5a in hippocampal neurons, involve the regulation of several 
miRNAs including miR-101b, which has the capacity to regulate several targets, including COX-2 in the central nerv-
ous system.
© 2016 Codocedo and Inestrosa. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The Wnt proteins constitute a large family of cysteine-
rich secreted glycoproteins, which are present in all ani-
mal species. The genome of mice and humans, has 19 
independent genes which are expressed in a tissue-spe-
cific form and also dependent on the development [1]. 
Wnts have been implicated in several cellular processes, 
such as cell proliferation, migration, polarity and cell fate 
specification [2, 3]. Moreover, the deregulation of Wnt 
signaling is related with several diseases, including autism 
[4, 5], schizophrenia [6, 7] and Alzheimer’s disease [7, 
8]. Wnt ligands couple to various receptors and thereby 
activate different signaling pathways. On the basis of 
early studies, these pathways have been classified as 
either canonical (β-catenin-dependent) or non-canonical 
(β-catenin-independent) signaling pathways. However, 
this classification can only serve as a rough guide, as vari-
ous divergent pathways has been described in different 
cellular contexts [9].
The role for Wnt signaling in synaptic formation and 
function has been clearly established [10–12]. In fact, 
we described that Wnt-5a, which preferentially activates 
non-canonical pathways [9], exerts important effects 
in the postsynaptic region of central synapses. Wnt-5a 
stimulation increases the postsynaptic density protein 
95 (PSD-95) clustering [13] and increases the density 
of dendritic spines [14]. In hippocampal slices, Wnt-
5a enhances long-term potentiation (LTP) modulating 
synaptic activity and plasticity [15, 16]. These findings 
strongly suggest that Wnt-5a regulates the assembly and 
function of the excitatory postsynaptic region of central 
synapses [17]. However, the mechanism underlying these 
effects is still elusive.
MicroRNAs (miRNAs) are a class of small non-cod-
ing RNAs that regulate the local translation of dendritic 
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mRNAs, affecting the morphology and function of den-
dritic spines [18]. MiRNAs control gene expression 
through specific base pairing between the 3′ UTR of 
mRNA and the miRNA “seed” region at the 5′ end [19]. 
We recently describe the miRNA biogenetic pathway in 
recent reviews [20, 21]. Briefly, canonical miRNAs are 
transcribed as primary miRNAs (pri-miRNAs, a long 
stem-loop precursor of several hundred nucleotides) 
which is cropped by the Microprocessor complex, com-
posed by DiGeorge Syndrome Critical Region 8 (DGCR8) 
and Drosha, a double-stranded RNA binding protein and 
an RNase III enzyme, respectively [22]. The resulting pre-
miRNA (~70  nt in length) is exported to the cytoplasm 
by Exportin-5 in a GTP-dependent fashion [23]. In the 
cytoplasm, pre-miRNA is cleaved into a ~22  nt mature 
miRNA duplex by Dicer, a second RNAse III enzyme. 
One strand of the mature miRNA duplex is loaded into 
the miRNA-induced silencing complex (miRISC) with 
members of the Argonaute family of proteins, producing 
a functional complex for targeting mRNA via direct base 
pairing [24]. The resulting miRNA/mRNA hybrids alter 
protein expression of the targeted mRNA by different 
mechanisms, including translational repression or mRNA 
degradation [25]. Some miRNAs have alternative biogen-
esis process, because they can bypass the action of some 
processing complexes. This is mainly due to structural 
differences in the precursors, which allow processing by 
other protein complexes such as the spliceosome. These 
exceptions are known as non-canonical pathways [26].
Interestingly, several reports have shown that miR-
NAs are downstream mediators of different extracellular 
stimuli, such as glutamate [27], dopamine [28], serotonin 
[29] and brain-derived neurotrophic factor (BDNF) [30], 
contributing to the induction and consolidation of plastic 
changes triggered by these synaptogenic factors.
In the present study, we provided evidence for a new 
mechanism underlying the neuronal effects of Wnt-5a, 
describing a number of miRNAs responsive to this ligand 
in hippocampal neurons. We focused on miR-101b, the 
most affected miRNA through Wnt-5a signaling, and 
their target COX2, an inducible enzyme that converts 
arachidonic acid to prostanoids, and has been related 
to the injury/inflammatory response [31, 32], and more 
recently to neuronal plasticity [33–36]. The downregu-
lation of miR-101b could contribute to the increase in 
COX2 expression observed during prolonged exposure 




Sprague-Dawley rats were housed in the University Ani-
mal Facility and handled according to the guidelines 
outlined and approved through the Institutional Animal 
Care and Use Committee at the Faculty of Biological Sci-
ences of the Pontificia Universidad Católica de Chile, and 
following the guidelines of the American Physiological 
Society Rockville, MD, USA.
Primary culture of rat hippocampal neurons
Rat hippocampal cultures were prepared as previously 
described [37, 38]. Primary hippocampal neurons were 
obtained from 18-day-old Sprague-Dawley rat embryos 
and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10 % horse serum for 2 h. 
The culture medium replaced with Neurobasal medium 
supplemented with B27, 100  µg/ml streptomycin, and 
100 units/ml penicillin. At 3 days in vitro (DIV), the cells 
were treated with 2  µM Cytosine Arabinoside C (araC) 
for 24 h to reduce the number of glial cells present in the 
culture. For the miRNA expression studies, 800,000 cells 
per well were seeded. For western blot (WB) analyses, 
400,000 cells per well were seeded, and for immunofluo-
rescence studies, 35,000 cells were plated per well. At 14 
DIV, the neurons were stimulated with 50 µM of Foxy-5 
(a mimetic formylated hexapeptide of Wnt-5a) (Gen-
emed Synthesis, San Francisco, CA, USA) or 300 ng/mL 
of recombinant Wnt-5a (rWnt-5a) (R and D System, Min-
neapolis, MN, USA) resuspended in Neurobasal medium. 
Control neurons incubated with a scramble peptide in 
Neurobasal medium (Genemed Synthesis, San Francisco, 
CA, USA) for experiments with either FOXY-5 or the 
carrier (BSA 0.1  %) resuspended in neurobasal medium 
for experiments with rWnt-5a. Incubations were con-
ducted at 37 °C.
HT22 cell line
HT22 murine hippocampal neuronal cells were main-
tained in DMEM supplemented with 10  % fetal bovine 
serum, 100 µg/ml streptomycin, and 100 units/ml peni-
cillin, high glucose and incubated at 37 °C under 5 % CO2 
as previously described [39]. Transfections were per-
formed after 2 days at approximately 60 % confluency.
RNA extraction and Real‑time PCR‑based miRNA 
expression profiling
Total RNA extraction and subsequent enrichment of 
small RNAs (<200 nt) was performed using the miRVana 
kit (Ambion) according to the manufacturer’s instruc-
tions [40]. The quantity and purity of the RNA samples 
were assessed using a NanoDrop 2000 Spectrophotom-
eter (Thermo Scientific). The integrity of the small RNAs 
was assessed on denaturing 15 % polyacrylamide gels.
First-strand cDNA was synthesized from 150  ng of 
small RNA using the RT2 miRNA First Strand kit (SABio-
sciences). RT2 miRNA PCR array was performed with an 
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Mx3000p qPCR system (Stratagene). The reactions, con-
taining 2X RT2 SYBR PCR master mix and diluted cDNA 
in a final volume of 25 μl, were amplified at 95 °C, 15 s; 
60  °C, 30 s; 72  °C, 30 s for 40 cycles. The miRNA input 
was normalized to endogenous controls (Rnu6, U87, 
4.5S-V1 and Y1), and the data analysis was performed 
using the web-based software package for the miRNA 
PCR array system using the comparative ΔΔCt method 
[41]. The fold-change was calculated for each miRNA 
from cells treated with Foxy-5 compared with control, 
represented as 2(−ΔΔCt), and the results were expressed as 
the fold-regulation by taking the negative inverse of any 
number less than 1, changing the fractional number into 
a whole number.
To evaluate the expression of COX-2 mRNA, 20  μg/
μl of total RNA was used for cDNA synthesis using the 
GoScript Reverse Transcription System (Promega). The 
determination of the mRNA abundance of specific genes 
was assessed through quantitative PCR (qPCR), using the 
StepOne 48-well Real-Time PCR System (Applied Bio-
systems, Carlsbad, CA, USA) and Fast SYBR Green Mas-
ter Mix (Applied Biosystems) reagent for amplification, 
using 4 μl cDNA, 4 μl DEPC water, 10 μl Master Mix, 1 μl 
Reverse Primer, and 1 μl Forward Primer in a total vol-
ume of 20 μl/well. The housekeeping gene was GAPDH 
(forward primer: 5′-CACGGCAAGTTCAACGGC-3′; 
reverse primer 5′-GGTGGTGAAGACGCCAGTA-3′) 
at an annealing temperature of 60  °C. The following 




For computational prediction of the miRNA targets, we 
used the TargetScan web platform [42], which predicts 
biological targets of miRNAs by searching for the pres-
ence of conserved 8- and 7-mer sites that match the seed 
region of each miRNA. In addition, TargetScan exam-
ines the binding sites for thermodynamic stability using 
RNAfold from the Vienna RNA Package [43]. For test-
ing enrichment in specific KEGG pathways of miRNA 
targets, we used DIANA-mirPath [44]. The software 
performs an enrichment analysis of multiple miRNA 
target genes comparing each set of miRNA targets with 
all known KEGG pathways. The combinatorial effect of 
co-expressed miRNAs in the modulation of a given path-
way was considered through the simultaneous analysis of 
multiple miRNAs.
miR‑101b gain‑of‑function
For miR-101b gain-of-function, we used mirVana 
miRNA mimic (Life Technologies), which represents a 
partially double-stranded RNA that mimics endogenous 
precursor miRNA and is processed to form an active 
miRNA molecule that targets specific mRNAs [45]. For 
miR-101b gain-of-function in HT-22 cells, Lipofectamine 
2000 reagent (Invitrogen, Karlsruhe, Germany) was used 
according to the manufacturer’s protocol. At 48  h post-
transfection, cells were used for western blotting (WB) 
or immunofluorescence analysis. For controls condi-
tions HT22 cells was transfected with mirVana miRNA 
Mimic Negative Control #1 (Life Technologies, Carlsbad) 
which correspond to a random sequence miRNA mimic 
molecule that not produce identifiable effects on known 
miRNA function.
Western blot analysis
The extraction of total protein from cell culture of hip-
pocampal neurons and immunoblot analysis were per-
formed as previously described [46, 47]. The following 
primary antibodies were used: rabbit anti-COX-2 
(1:1000; ABCAM) and anti GAPDH (1:10,000, Santa 
Cruz). Primary antibodies were recognized using either 
a horseradish peroxidase (HRP)-conjugated goat anti-
rabbit antibody (1:7000, Thermo Scientific) or an HRP-
conjugated rabbit anti-mouse antibody (1:7000, Thermo 
Scientific). The secondary antibodies were detected 
through enhanced chemiluminescence using the ECL 
Plus WB detection system (GE Healthcare). Densi-
tometric analysis was performed using NIH ImageJ 
software.
Immunofluorescence analysis
Immunofluorescence studies were performed as previ-
ously described [46, 47]. Briefly, after stimulation, the 
cells were rinsed twice in ice- cold PBS and fixed with a 
freshly prepared solution of 4  % paraformaldehyde and 
4 % sucrose in PBS for 20 min at 4 °C and permeabilized 
with 0.2 % Triton X-100 for 5 min in PBS at room tem-
perature. After several rinses in ice-cold PBS, the cells 
were incubated in 1  % BSA in PBS (blocking solution) 
for 30  min at room temperature, followed by an over-
night incubation at 4  °C with primary antibodies. The 
cells were extensively washed with PBS and subsequently 
incubated with Alexa-conjugated secondary antibod-
ies for 60 min at 37 °C. The coverslips were mounted in 
mounting medium, and image stacks were collected in 
0.25  µm z-step sizes using an Olympus LSM Fluoview 
1000 confocal microscope. The images in the figures are 
maximum intensity projections to obtain high contrast 
images, but the quantifications were made over aver-
age intensity projections. An outline was drawn around 
each cell and total fluorescence measurements were per-
formed with NIH ImageJ software.
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Statistical analysis
All data were analyzed statistically with Prism 5 (Prism 
GraphPad Software, GraphPad Software Inc., La Jolla, 
CA, USA) using the Mann-Whitney U test or one-way 
ANOVA, followed by Bonferroni-corrected pairwise 
comparisons. The error bars indicate SEM. A p  <  0.05 
was considered statistically significant.
Results
Wnt‑5a signaling regulates the expression levels of miRNAs 
in hippocampal neurons
Various functions of different cell types in the mam-
malian brain suggest that some miRNAs are differen-
tially expressed in glia and neurons in response to the 
same stimuli [48, 49]. To determine whether Wnt-5a 
modulates neuronal miRNAs, we profiled miRNAs in 
cultured hippocampal neurons with a low glial content 
(see “Methods” section). These cultures were treated 
with Foxy-5, a mimetic formylated hexapeptide of Wnt-
5a, extensively used for the reproduction of the biologi-
cal effects of this ligand [50–53]. Foxy-5 mimics the full 
Wnt-5a molecule in cultures of hippocampal neurons 
[13, 16, 54, 55]. Among the 264 miRNAs tested after 
1 h of stimulation, 8 % miRNAs were not detected, 37 % 
miRNAs showed low detection and 27 % miRNAs were 
abundantly expressed. The remaining 28 % miRNAs were 
abundantly detected in at least one of the experimental 
conditions (control or treated) (Fig. 1a). Consistent with 
the suggestions of the supplier, for the next analysis, we 
used only a fraction of miRNAs abundantly detected in at 
least one of the samples (cyan and red groups in Fig. 1a). 
In addition, to be considered as a regulated miRNAs, a 
minimum of fivefold regulation was used as an inclusion 
criteria as previously described [48]. In this fraction, we 
observed significant changes in 34 miRNAs (p  <  0.05). 
Three of these miRNAs showed increased expres-
sion (miR-24, -146b and -153) and 31 miRNAs showed 
decreased expression (Fig. 1b).
Biological function of the miRNAs modified by Wnt‑5a 
signaling
Using the online software TargetScan, we predicted a list 
of target genes for the miRNAs genes modulated through 
Foxy-5. To understand the functional significance of 
these targets, we used the online software, Diana miR-
path, which identifies biological processes downstream 
of miRNAs altered through Wnt-5a signaling. The major 
biological functional categories targeted by downregu-
lated miRNAs are enriched in pathways associated with 
cancer. Other pathways were associated with synaptic 
processes, such as MAP-kinase signaling, focal adhe-
sion, mTOR signaling, axon guidance, regulation of actin 
cytoskeleton and Wnt signaling (Fig.  1c). Altogether, 
these results suggest the possible roles and mechanisms 
of these differentially expressed miRNAs and their tar-
gets in the presence of the Wnt-5a ligand.
Mir‑101b gain‑of‑function downregulates COX2 expression
Considering that Wnt-5a signaling generates a significant 
decrease in the levels of miR-101b (Fig. 1b), we reasoned 
that the levels of some of the predicted targets could be 
increased in the presence of Wnt-5a. Among these tar-
gets, we focused on COX2, an enzyme expressed in dis-
crete populations of neurons and is enriched in the cortex 
and hippocampus [56] and has been implicated in brain 
functions and in neurologic disorders, including Alz-
heimer’s disease [57]. The miRNAs recognition element 
(MRE) in the 3′UTR of COX2 is a canonical binding site 
(8-mer) broadly conserved among mammals (Fig. 2a, b). 
To validate the in silico prediction of COX2 as a target 
of miR-101b, we introduced a miRNA mimic into HT22 
cells and evaluated the expression of endogenous COX2 
through WB (Fig. 2c). It is apparent that the increase of 
miR-101b decreases the level of COX2 in a dose-depend-
ent manner (Fig. 2d). The same effects were observed in 
immunofluorescence experiments in HT22 cells using 
the maximal efficacy concentration of miR-101b mimics 
(data not show). These results validate the in silico pre-
diction of COX2 as a target of miR-101b and suggest that 
COX2 expression could be modulated through Wnt-5a 
signaling via miR-101b.
Wnt‑5a treatment increases the expression of COX2 
in cultured hippocampal neurons
The expected outcome of a decrease in miRNA levels is 
that the translation of the target increases, and as a con-
sequence, the target protein levels also might increase. 
Using WB analyses, we determined that treatment with 
Wnt-5a increases the levels of COX2 in a time-depend-
ent manner in cultured hippocampal neurons (Fig.  3a, 
b). Complementary immunofluorescence studies con-
firm this observation, because Wnt-5a increases the 
somatic and dendritic signal of COX-2 at 1  h of stimu-
lation (Fig.  3c, d). This increase is coincident with the 
previously described decrease in miR-101b triggered 
through Wnt-5a signaling activation (Fig.  1b). Using 
qPCR, we measured the expression of COX2 mRNA to 
determine whether this effect is dependent on a tran-
scriptional mechanism. At 1 h of stimulation, we did not 
detect changes in the levels of COX2 mRNA expression 
(Fig.  3e), suggesting a post-transcriptional mechanism, 
consistent with the miR-101b decrease.
Discussion
Previous studies indicated that Wnt-5a is a synaptogenic 
factor, whose expression increases during development; 
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indicating that Wnt-5a plays an important role in syn-
aptic structure and function in the adult nervous system 
[17, 58]. Neural factors induce plastic changes through 
the activation of different signaling pathways, including 
the modulation of specific miRNAs [59]. In the present 
study, we evaluated the hypothesis that treatment with 
Wnt-5a modulates miRNAs in hippocampal neurons 
and this modulation contributes to the neuronal effects 
previously described for the Wnt ligand through the reg-
ulation of different targets. We identified more than 30 
miRNAs with differential expression after 1 h treatment 
with the Wnt-5a mimetic peptide. Most of the regulated 
miRNAs showed decreased expression, and only 3 miR-
NAs showed increased expression, suggesting that these 
two groups of miRNAs have different Wnt responsive 
elements in their biogenetic pathway. Further studies are 
necessary to determine the mechanism by which Wnt-
5a controls the expression of miRNAs in hippocampal 
neurons.
To understand the role of the miRNAs regulated 
through Wnt-5a, we used bioinformatics tools to obtain 
the predicted targets and determine the potential roles 
for these genes in biological pathways using the KEEG 
database. The top KEGG pathways of biological function 
for the targets of downregulated miRNAs showed enrich-
ment in cancer processes. This finding is important, since 
Wnt-5a is upregulated in several types of cancer. For 
example, Wnt-5a is increased in melanoma [60], colo-
rectal cancer [61], pancreatic cancer [62], non-small cell 
lung cancer [63, 64], renal cell carcinoma [64] and glioma 
[65, 66]. The only exception to this, is myeloid leukemia, 
in which Wnt-5a is downregulated and functions as a 
Fig. 1 Foxy-5, a mimetic peptide of Wnt-5a, regulates miRNA expression levels in hippocampal neurons. a The pie chart shows the percentage 
expression of 263 rat miRNAs in hippocampal neurons treated with Foxy-5 and control (n = 3, each). b Fold-regulation of miRNAs expression in 
neurons treated with Foxy-5 (p < 0.05, n = 3). Among the 34 significantly modulated miRNAs, miR-101b was the most affected. c The top KEGG 
pathways of biological function of the targets of downregulated miRNAs after Foxy-5 treatment
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tumor suppressor [67]. This correlation suggests an asso-
ciation between the in silico prediction and the known 
effects of Wnt-5a. However, the enrichment analysis 
showed some pathways with a specific role in the regu-
lation of synaptic plasticity process, such as the MAPK 
signaling, focal adhesion, axon guidance, regulation of 
actin cytoskeleton and Wnt signaling, which is consistent 
with our hypothesis.
MiR-101b was the most affected miRNA in hip-
pocampal neurons after Wnt-5a signaling activation. 
This miRNA has been described as a tumor suppressor 
that inhibits the expression of oncogenes, such as RAB 
GTPase 5A (RAB5A) [68] and enhancer of zeste 2 (EZH2) 
[69]. A number of studies have shown that the expression 
of miR-101b is significantly decreased in multiple types 
of cancer, such as colon cancer [70–72], in which, as pre-
viously noted, Wnt-5a levels are increased. The same rela-
tionship has been observed in Alzheimer’s disease, where 
the levels of miR-101b are reduced [73–75], but the levels 
of Wnt-5a are increased [76]. Since the role of miR-101b 
has been investigate in cancerogenesis, the roles for miR-
NAs in the brain have just begun to emerge. MiR-101b 
regulates the expression of a key protein in Alzheimer´s 
disease, the amyloid precursor protein (APP) [77–79], as 
well as other proteins involved in neurological diseases 
such ataxin1 [80], and the Autism protein the Fragile X 
Mental Retardation gene 1 (FMR1) [81], moreover, a key 
synaptic protein SynGAP1 [82] has been also detected 
in the hippocampus. Among the many targets predicted 
for miR-101b, we investigated COX2 for two reasons. 
First, the relationship between miR-101b and COX2 has 
been previously describe in several cancer cell lines and 
tumors, and we want to determine whether this regu-
lation is conserve in hippocampal neurons and if it is 
regulated by Wnt-5a. Second, COX2 has been related to 
inflammation, synaptic plasticity and Alzheimer disease, 
which correspond to biological processes in which Wnt-
5a is involved and plays a key role.
We validated the in silico prediction through the down-
regulation of the endogenous levels of COX2, using 
miR-101b mimics in HT22 cells. The expected outcome 
of a miRNA decrease is that the expression of the tar-
get proteins increases. Wnt-5a generates an increase 
in the protein levels of COX2 after 1  h of treatment in 
cultured hippocampal neurons. Immunofluorescence 
analysis and confocal microscopy confirm that treatment 
Fig. 2 COX2 is a target of downregulated miR-101b in hippocampal neurons. a Complementarity of the sequences between miR-101b and the 
COX2 3′-UTR of rat genome obtained from TargetScan. b The predicted binding site for the seed sequence of miR-101b in the 3′UTR of COX2 is 
conserved among several species. c Endogenous levels of COX2 are significantly decreased through gain-of function of miR-101b mimics in HT22 
cells d Densitometric analysis of the WB shown in c (*p < 0.05, n = 4)
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with rWnt-5a is able to induce the expression of COX-
2. The localization of COX-2 in basal conditions was 
detected mainly in the nucleus, which is consistent with 
the location previously described in cortical neurons, 
both by electron microscopy and immune-gold tech-
niques, which was determined at the level of the luminal 
surface of the nuclear membrane [83]. Besides, a weaker 
level of cytosolic signal was found (Fig. 3c upper panel). 
Treatment with rWnt-5a generated a significant increase 
in fluorescence intensity of COX2, which is distributed 
throughout the somato-dendritic compartment (Fig.  3c 
lower panel, d). Interestingly, the mRNA levels of COX2 
were not affect at 1 h of stimulation (Fig. 3e), suggesting 
that the increase in their protein levels is dependent on 
a post-transcriptional mechanism consistent with the 
function of the miRNAs.
The functional consequence of COX2 increase is relate 
to the pro-inflammatory effect of Wnt-5a, described pre-
viously. Wnt-5a, which is expressed in astrocytes in the 
adult mouse brain, evokes a microglia pro-inflammatory 
transformation characterized by an increase in the 
expression of cytokines, chemokines and metallopro-
teases and changes in microglial proliferation and inva-
siveness. In a recent study, astrocytes and microglial cells 
prepared from newborn C57Bl 6 mice, was treated with 
300 ng/mL of rWnt-5a (same amount used in this study) 
which generate a modest increase in the mRNA and pro-
tein levels of COX2 after 6 h, which is increased when the 
amount of rWnt-5a is raised up to 1000 ng/mL [84, 85]. 
Interestingly, in human aortic endothelial cells (HAECs), 
the treatment with rWnt-5a by 1  h, generates a robust 
increase in the protein and mRNA of COX2, however, 
Wnt-5a did not up-regulate the mRNA levels of COX-2 
in other cell types, such as SH-SY5Y, HeLa, HEK293T, 
and RAW264.7, suggesting that Wnt-5a-induced inflam-
matory gene expression was specific for endothelial cells 
[86]. The signaling mediated by Wnt ligands are highly 
dependent of the cellular context [87], and this could be 
the reason of the observed differences in the induction of 
COX2 in different cellular models.
Fig. 3 Wnt-5a treatment increases the expression of COX2 in a time-dependent manner. a WB analysis of COX2 levels in hippocampal neurons 
treated with recombinant Wnt-5a (300 ng/mL) at different time points. b Densitometric analysis of the WB experiments shown in a. The results are 
presented as the mean of n = 5 experiments, and the statistical analysis was performed using one-way ANOVA, followed by post hoc Bonferroni’s 
analysis *p < 0.05 c Immunofluorescence analysis of COX2 expression in hippocampal neurons. Upper panel Representative images of control hip-
pocampal neurons at 14 DIV. Lower panel Representative images of hippocampal neurons treated with rWnt-5a (300 ng/mL) for 1 h at 14 DIV (COX2 
Blue, β-III-Tubulin green. White bar corresponds to 20 μm). d Quantification of somatic mean fluorescence intensity. n = 3, and the statistical analysis 
was performed using the Mann-Whitney U test * p < 0.05. e Analysis of COX2 mRNA expression using quantitative real-time PCR in hippocampal 
neurons treated for 1 h with rWnt-5a (300 ng/mL) at 14 DIV. The results are normalized to GAPDH expression and represented as the mean of n = 3 
experiments. The statistical analysis was performed using the Mann–Whitney U test (NS, no significant changes)
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At difference of other tissues, COX-2 is also constitu-
tively expressed in brain [56], suggesting that their basal 
activity is involved in general cellular functions. In brain, 
both COX-2 mRNA and protein are express at relatively 
high levels in neurons involved in plastic and cogni-
tive functions, such as those hippocampal granule cells, 
pyramidal cells, and cortical neurons. In fact, COX-2 
protein is express at a very high level in dentate granule 
cells under basal conditions [56].
Basal expression of COX-2 is regulate by the synaptic 
activity, and its cellular expression is upregulated by a 
high-frequency stimulation (HFS) associated with LTP 
induction [56]. Moreover, COX-2 is present in neuronal 
dendritic spines where excitatory synapses are located 
[88]. These evidences imply that COX-2 plays an impor-
tant role in synaptic modifications. Based in our previous 
work, in which Wnt-5a induces an enhancement of the 
synaptic structure and function, the observed increase 
in the COX2 levels through miR-101b, is related to their 
role as synaptic modulator. Additional experiments are 
required to determine the mechanism by which Wnt-5a 
regulates the expression of miRNAs, in particular miR-
101b and also the physiological conditions in which the 
module miR-101b/COX2 contribute to the brain func-
tion regulated by the Wnt-5a ligand.
Based on the results obtained in the present study, we 
propose a hypothetical model, in which Wnt-5a increases 
the expression of COX2 through the regulation of miR-
101b, which in turn could participate in biological 
processes well described of Wnt-5a such as a pro-inflam-
matory response or synaptic plasticity (Fig. 4).
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